Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study.

MLA

Poveda, Andres, et al. “Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study.” Cancers, vol. 14, no. 4, Feb. 2022, p. 915. EBSCOhost, https://doi.org/10.3390/cancers14040915.

APA

Poveda, A., Lopez-Reig, R., Oaknin, A., Redondo, A., Rubio, M. J., Guerra, E., Fariñas-Madrid, L., Gallego, A., Rodriguez-Freixinos, V., Fernandez-Serra, A., Juan, O., Romero, I., & Lopez-Guerrero, J. A. (2022). Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study. Cancers, 14(4), 915. https://doi.org/10.3390/cancers14040915

Chicago

Poveda, Andres, Raquel Lopez-Reig, Ana Oaknin, Andres Redondo, Maria Jesus Rubio, Eva Guerra, Lorena Fariñas-Madrid, et al. 2022. “Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study.” Cancers 14 (4): 915. doi:10.3390/cancers14040915.